AUTHOR(S): Mezzour M, Elharti K and Elwady W

ABSTRACT:Pemphigus vulgaris is an intraepidermal autoimmune dermatosis characterized by autoantibodies directed against desmoglein 1 and / or 3, which are transmembrane proteins constituting desmosomes.
It is a potentially fatal pathology, with very painful cutaneous and mucous manifestation. A reasoned and early management is of great interest. The European Dermatology Forum’s (EDF) recommendations (October 2016), based on the High Authority for Health’s (HAS) recommendations (April 2016), have established a precise care approach. Diagnosis is raised by clinical features; then confirmed by histological aspect and direct immunofluorescence. Treatment is based on general corticosteroid therapy for a prolonged period. The adjonction of immunosuppressants is often useful for cortisone sparing. The HAS also established recommendations for the oral management of patients with oral pemphigus vulgaris. These recommendations are intended to reduce the lesions’s symptomatology and to improve the patient’s quality of life.

Pages: 289-292  |  1346 Views  188 Downloads